MA
CABA icon

MYDA Advisors’s Cabaletta Bio CABA Stock Holding History

MYDA Advisors’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40,000
Closed -$60.8K – 166
2025
Q2 		$60.8K Buy
+40,000
New +$62.4K 0.01% 138
2025
Q1 		– Sell
-171,200
Closed -$389K – 152
2024
Q4 		$389K Buy
+171,200
New +$601K 0.1% 116

Other funds holding CABA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return

MYDA Advisors's CABA Position: Q3 2025 in Review

MYDA Advisors sold out of Cabaletta Bio (CABA) in Q3 2025, closing a stake of 40,000 shares — an estimated $60.8K sold.

MYDA Advisors first reported a position in CABA in Q4 2024 and held it in 2 quarters. The position peaked at $389K in Q4 2024. 75 funds tracked by Wall St. Rank hold CABA as of Q3 2025.

  • MYDA Advisors reported no remaining Cabaletta Bio position as of Q3 2025 after selling out during the quarter.
  • MYDA Advisors sold 40,000 Cabaletta Bio shares in Q3 2025, an estimated $60.8K.
  • MYDA Advisors first reported a position in Cabaletta Bio in Q4 2024 and held it in 2 quarters.
  • MYDA Advisors's Cabaletta Bio position peaked at $389K in Q4 2024.
  • 75 funds tracked by Wall St. Rank held Cabaletta Bio as of Q3 2025.

Based on MYDA Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.